#ESHCML2022 LIGHT UPON THE MAIN SCIENTIFIC TOPICS

 

24^th ANNUAL JOHN GOLDMAN CONFERENCE ON
CHRONIC MYELOID LEUKEMIA:
BIOLOGY AND THERAPY

 

October 21-23, 2022
Mandelieu-La Napoule, France - #ESHCML2022

Co-organizers: R. Bathia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel,
F-X. Mahon, D. Perrotti, J. Radich, D. Réa
Advisory Committee: J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot,
R. Hehlmann, P. Laneuville, G. Saglio, C. Schiffer, S. Soverini, P. Valent, R. Van Etten

---

Here are the main scientific topics of #ESHCML2022:

STEM CELLS AND MICROENVIRONMENT
METABOLISM AND NEW TARGETS
GENOMICS
NEW DRUGS AND NEW STRATEGIES
TFR AND PRO
REAL WORLD DATA
PEDIATRICS, BIOMARKERS AND COVID

---

The program starts on October 21st, in less than a month!
Have you registered yet?

---

ABOUT THE CONFERENCE

Strong basic and clinical science:

Speakers at this meeting will present new, often unpublished data related to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells, approaches to cure and treatment free remission.

The program will include

- Special Lectures
- Keynote Lectures
- Oral Communications selected from Submitted Abstracts
- Workshops for Non-Clinical Scientists
- Mentored Poster Walks: Clinical and Biology
- Michele Baccarani Special Symposium (topic to be announced)
- The John Goldman Prize Ceremony and Lecture
- The Janet Rowley Prize Ceremony and Lecture
- The iCMLf Prize Ceremony and Lecture
- The ESH John Goldman International Research Award ceremony and scientific presentation

MORE INFORMATION

LOCAL COVID-19 RULES

---

With the support of*:



Diamond Conference Partner
*******

*ESH conference programs are developed in strict scientific independence
with no input from corporate sponsors.